The trading price of Lineage Cell Therapeutics Inc (AMEX:LCTX) closed lower on Friday, May 23, and closing at $0.69, -1.79% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $0.6707 and $0.76. In examining the 52-week price action we see that the stock hit a 52-week high of $1.15 and a 52-week low of $0.37. Over the past month, the stock has gained 40.04% in value.
Lineage Cell Therapeutics Inc, whose market valuation is $156.70 million at the time of this writing, is expected to release its quarterly earnings report on 2025-May-12. Investors’ optimism about the company’s current quarter earnings report is understandable.
On the technical side, indicators suggest LCTX has a Hold on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Sell, while an average of long term indicators suggests that the stock is currently 50% Buy.
A quick review shows that LCTX’s price is currently 36.74% off the SMA20 and 44.53% off the SMA50. The RSI metric on the 14-day chart is currently showing 73.32, and weekly volatility stands at 8.84%. When measured over the past 30 days, the indicator reaches 6.67%. Lineage Cell Therapeutics Inc (AMEX:LCTX)’s beta value is currently sitting at 1.51, while the Average True Range indicator is currently displaying 0.05.
To see how Lineage Cell Therapeutics Inc stock has been performing in comparison to its peers in the industry, here are the numbers: LCTX stock’s performance was -1.79% in the latest trading, and -34.65% in the past year.
An evaluation of the daily trading volume of Lineage Cell Therapeutics Inc (AMEX:LCTX) indicates that the 3-month average is 1.34 million. However, this figure has increased over the past 10 days to an average of 1.15.
Currently, records show that 228.36 million of the company’s shares remain outstanding. The insiders hold 0.44% of outstanding shares, whereas institutions hold 48.71%. The stats also highlight that short interest as of 2025-04-30, stood at 30.0 million shares, resulting in a short ratio of 23.99 at that time. From this, we can conclude that short interest is 2345.00 of the company’s total outstanding shares. It is noteworthy that short shares in April were up slightly from the previous month’s figure, which was 26.64 million. However, since the stock’s price has seen 36.56% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
